Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$45.40 USD

45.40
14,580,623

+1.17 (2.65%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $45.38 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

by Zacks Equity Research

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Zacks Equity Research

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

by Zacks Equity Research

Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.

Zacks Equity Research

Is it a Good Idea to Invest in Immunocore Stock Right Now?

by Zacks Equity Research

IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.

Ekta Bagri headshot

Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?

by Ekta Bagri

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Zacks Equity Research

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

Zacks Equity Research

J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study

by Zacks Equity Research

Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.

Zacks Equity Research

Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

by Zacks Equity Research

PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.

Sweta Killa headshot

A Look at Pharma ETFs After Strong Q1 Earnings

by Sweta Killa

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

Zacks Equity Research

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

The Zacks Analyst Blog Highlights Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle

by Zacks Equity Research

Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), Bristol-Myers Squibb Co. (BMY) and Canadian Pacific Kansas City Ltd. (CP), as well a micro-cap stock Nova LifeStyle, Inc. (NVFY).

Zacks Equity Research

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Zacks Equity Research

Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales

by Zacks Equity Research

PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.

Zacks Equity Research

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEY

Ekta Bagri headshot

BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?

by Ekta Bagri

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.

Zacks Equity Research

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Company News for Apr 25, 2025

by Zacks Equity Research

Companies in The News Are: BMY,MRK,PEP,UNP

Zacks Equity Research

BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook

by Zacks Equity Research

BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.

Zacks Equity Research

Jobless Claims Increased in Line With Expectations

by Zacks Equity Research

Jobless Claims Increased in Line With Expectations

Mark Vickery headshot

A Busy Morning: Jobless Claims, Durable Goods & Q1 Earnings

by Mark Vickery

While Jobless Claims and Durable Goods outperformed, we saw mixed results in Q1 earnings this morning.

Zacks Equity Research

Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.